In this episode, we examine diranersen, also known as BIIB080, and the Phase 2 CELIA clinical trial. This experimental tau-targeting therapy reportedly reduced tau levels by 50–65% and was associated with slower cognitive decline on several testing measures.
The most surprising result was that the lowest dose appeared to perform best. That created an important scientific complication: the trial was designed to show that higher doses would produce greater benefits, but the results did not follow that pattern. Technically, the trial missed its primary endpoint, even though the biomarker and cognitive findings were encouraging.
We also discuss the reported safety results, including the absence of ARIA cases commonly associated with some amyloid-targeting treatments, and why the findings still need to be confirmed in Phase 3 testing.
The CELIA data had been presented at AAIC but had not yet been peer-reviewed or published in a medical journal at the time covered by this episode.
This is an educational discussion, not medical advice. Diranersen is an investigational drug and should not be considered an approved treatment for Alzheimer’s disease.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.